NCT06066645RecruitingPhase 4
Travoprost Intraocular Implant + iStent Infinite
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose® TR (Travoprost Intraocular Implant) in Conjunction With the Placement of iStent Infinite in Subjects With Open-angle Glaucoma or Ocular Hypertension
Source: ClinicalTrials.gov · Last updated 2 Jun 2026
Brief summary (registry, in English)
Adult subjects with elevated intraocular pressure will be randomized to receive iStent infinite trabecular bypass system plus a travoprost intraocular implant or receive a sham procedure plus a travoprost intraocular implant and be followed for 12 months.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 150 (estimated)
- First submitted
- 27 Sept 2023
- Start date
- 14 Sept 2023
- Primary completion date
- May 2027
- Lead sponsor
- Glaukos Corporation
- Diseases
- Glaucoma, High blood pressure
- NCT number
- NCT06066645
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 150
- From 14 Sept 2023 to the primary completion date, May 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- hypersensitivity to travoprost or any other components of the travoprost intraocular implant
- any ocular disease or condition that, in the opinion of the investigator, may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study
Other
- unmedicated (washed out) IOP of \>36 mmHg in the study eye
- vertical cup/disc ratio \> 0.8 in the study eye
- best spectacle corrected visual acuity of worse than 20/80 in either eye
Who the study is looking for
- diagnosis of open-angle glaucoma or ocular hypertension
- qualifying IOP in the study eye
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | Oklahoma City | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.